Drugs / CV9202
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01915524 | Apr 2013 → Jul 2016 | non-small cell lung carcinoma | CureVac | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CV9202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01915524 ↗ |
| Known as | BI1361849 | “BI1361849 (CV9202) is an active cancer immunotherapeutic comprising protamine-formulated, sequence-optimized mRNA encoding six non-small cell lung cancer (NSCLC)-associated antigens” PMID 30736848 ↗ Feb 2019 |
| Modality | Messenger RNA (mRNA) | “CV9202 is a self-adjuvanting mRNA vaccine” PMID 25288198 ↗ Oct 2014 |
| Route | Other | “Intradermal injection of CV9202” NCT01915524 ↗ |